Not exact matches
In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy
drug,
dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same
drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutations.
Around 40 to 50 per cent of melanoma patients have a faulty BRAF gene and they can be treated with the targeted
drugs vemurafenib or
dabrafenib.
These are the BRAF - targeted oral
drugs,
dabrafenib and trametinib.
«These new data, demonstrating the impact of nivolumab and of
dabrafenib and trametinib on stopping melanoma coming back, show how we might use these
drugs earlier in the course of the disease.
«What we find is that
dabrafenib, even at high doses, does not fully turn off the MAPK pathway, thereby enabling eventual escape from
drug,» Spencer says.